National and Kapodistrian University of Athens
Μελέτη του πάχους του ενδοθηλιακού γλυκοκάλυκα και δεικτών αγγειακής λειτουργίας σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και λευκωματινουρία μετά απο χορήγηση ντουλαγλουτίδης και δαπαγλιφοζίνης έναντι DPP-4 αναστολέων
Abstract
dc:descriptionBACKGROUND: The association between diabetes mellitus and diabetic nephropathy with vascular and endothelial properties is well established. In this study, we compared the effect of combined treatment with dulaglutide and dapagliflozin versus DPP-4 inhibitors on endothelial glycocalyx, arterial stiffness, myocardial function and albuminuria in patients with type 2 diabetes mellitus and albuminuria. METHODS: A total of 60 patients with type 2 diabetes mellitus and albuminuria were randomized to combined dulaglutide and dapagliflozin treatment (n=30) or DPP-4 inhibitors (DPP-4is, n=30). We measured at baseline and 4 and 12 months posttreatment: (a) perfused boundary region of the sublingual arterial micro vessels (marker of endothelial glycocalyx thickness), (b) pulse wave velocity (PWV) and central systolic blood pressure(cSBP), (c) global left ventricular longitudinal strain (GLS) (d) urine albumin-to creatinine ratio (UACR).RESULTS: Twelve months posttreatment, the combination of dulaglutide and dapagliflozin showed a greater improvement in all indices compared to DPP-4is, despite a similar reduction in glycosylated hemoglobin. Specifically, dual therapy showed greater improvements vs DPP-4is in PBR (2,10±0,31 to 1,93±0,23 μm vs 2,11±0,31 to 2,08±0,28 μm, p(326±61 to 142±47 mg/g vs 345±48 to 306±60 mg/g, p(11,77±2,37 to 10,7±2,29 m/s vs 10,64±2,44 to 10,54±2,84 m/s, p only dual therapy showed improvement in cSBP (130,21±17,23 to 123,36±18,42 mmHg). Regarding GLS, both treatments were effective, but dual therapy showed a significantly higher percentage improvement compared to DPP-4is (18,19% vs 6,01%, respectively). CONCLUSIONS: Twelve-month treatment with dulaglutide and dapagliflozin showed a greater improvement in vascular markers an albuminuria than DPP-4is in patients with type 2 diabetes mellitus and albuminuria. Early initiation of combined therapy as add-on to metformin should be considered in these patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Korakas, Emmanouil
- Κόρακας, Εμμανουήλ
Subjects
dc:subject × 16- Σακχαρώδης διαβήτης
- Λευκωματουρία
- Αρτηριακή σκληρία
- Γλυκοκάλυκας
- Νεότερη αντιδιαβητική αγωγή
- Type 2 diabetes mellitus
- Albuminuria
- Arterial stiffness
- Glycocalyx
- Novel antidiabetic medication
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55914